发明名称 Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
摘要 Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
申请公布号 US8852626(B2) 申请公布日期 2014.10.07
申请号 US201213425217 申请日期 2012.03.20
申请人 Otonomy, Inc.;The Regents of the University of California 发明人 Lichter Jay;Lebel Carl;Piu Fabrice;Ye Qiang;Dellamary Luis A.;Trammel Andrew M.;Harris Jeffrey P.
分类号 A61F9/02;A61K9/00;A61K45/06;A61K31/195;A61K9/06;A61K47/14;A61K47/38;A61K31/00;A61K47/10;A61K31/5513;A61K31/167;A61K47/44 主分类号 A61F9/02
代理机构 Wilson, Sonsini, Goodrich & Rosati 代理人 Wilson, Sonsini, Goodrich & Rosati
主权项 1. A method of treating an otic disease or condition comprising administering an intratympanic composition on or near the round window membrane of an individual in need thereof, the intratympanic composition comprising: between about 0.01% to about 20% by weight of a micronized Central Nervous System (CNS) modulator, or pharmaceutically acceptable salt thereof; and a polyoxyethylene-polyoxypropylene copolymer in an amount sufficient to provide a gelation temperature between about 19° C. to about 42° C., and a gelation viscosity between about 15,000 cP and about 1,000,000 cP; and the intratympanic composition having an osmolarity of less than about 1000 mOsm/L; wherein the intratympanic composition provides a sustained release of a therapeutically effective amount of the CNS modulator across the round window membrane into the cochlea for a period of at least 5 days after a single administration.
地址 San Diego CA US